Herpès zoster
Update on the Use of Herpes Zoster Vaccine
Since the development of the 2010 statement, new data has been published with regards to the administration and safety of herpes zoster vaccine. n order to inform the recommendations of the National Advisory Committee on Immunization (NACI) made in this update, a systematic review of the literature was undertaken. This review focused on emerging literature since the previous statement as well as specific areas highlighted for review. Articles were obtained using a PubMed search from August 31, 2008 to September 30, 2012. Recommendations and llevels of evidence evaluations were agreed to by consensus of NACI members and were based on previously published NACI guidelines.
Fact Sheet – Shingles (Herpes Zoster)
This fact sheet provides information on shingles (herpes zoster), symptoms, risks, protection, and treatment.
Feuille de renseignements – Zona (herpès zoster)
Cette feuille de renseignements offre des informations sur le zona (herpès zoster), les symptômes, les risques, la protection contre le zona, et le traitement.
Update on herpes zoster vaccination: A family practitioner's guide
The objective of this Update is to answer frequently asked questions surrounding the use of the herpes zoster (shingles) vaccine.
Déclaration sur l'utilisation recommandée du vaccin contre le virus de l'herpès zoster
La présente déclaration fournit des recommandations pour l’utilisation de ZostavaxMC chez les adultes canadiens. À mesure que de nouveaux renseignements concernant ZostavaxMC et le fardeau de la maladie seront accessibles, ces recommandations seront révisées. Les questions relatives à la rentabilité, à l’acceptabilité et à la faisabilité des programmes de vaccination seront étudiées par d’autres groupes provinciaux ou fédéraux.
Statement on the recommended use of Herpes zoster vaccine
This statement provides recommendations for use of Zostavax in Canadian adults. As new information regarding Zostavax and/or the burden of illness becomes available, the recommendations will be reviewed. Issues including cost-effectiveness, acceptability of vaccine programs, and feasibility will be addressed by other provincial or federal groups.